Paediatric non-alcoholic fatty liver disease

Gut

Volumn 59, Issue 5, 2010, Pages 561-564

  Nobili, Valerio ^a   Pinzani, Massimo ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FAT; INSULIN;

BODY MASS; CLINICAL FEATURE; DEMOGRAPHY; ELASTOGRAPHY; HEALTH SURVEY; HISTOPATHOLOGY; HUMAN; HYPERALIMENTATION; INSULIN RESISTANCE; ITALY; LIFESTYLE MODIFICATION; LIPID STORAGE; LIVER BIOPSY; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOPHYSIOLOGY; PEDIATRICS; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOCIOECONOMICS;

ADOLESCENT; BIOPSY; CHILD; CHILD, PRESCHOOL; FATTY LIVER; HUMANS; LIVER; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 77951738835     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.187039     Document Type: Review

References (49)

1. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-1393 (Pubitemid 46393782)
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
3. Marchesini G, Brizi M, Bianchi G, et al. Metformin in nonalcoholic steatohepatitis. Lancet 2001;358:893-894.
4. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379 (Pubitemid 34106377)
5. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis following 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-1017.
6. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with nonalcoholic steatohepatitis. J Hepatol 2003;38:434-440.
7. Barshop NJ, Sirlin CB, Schwimmer JB, et al. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;28:13-24. (Pubitemid 351782810)
8. Alisi A, Manco M, Panera N, et al. Association between type two diabetes and non-alcoholic fatty liver disease in youth. Ann Hepatol 2009;8(Suppl 1):S44-50.
9. Patton HM, Sirlin C, Behling C, et al. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr 2006;43:413-427 (Pubitemid 44568999)
10. Papandreou D, Rousso I, Mavromichalis I. Update on non-alcoholic fatty liver disease in children. Clin Nutr 2007;26:409-415 (Pubitemid 47091479)
11. Dunn W, Schwimmer JB. The obesity epidemic and nonalcoholic fatty liver disease in children. Curr Gastroenterol Rep 2008;10:67-72.
12. Manco M, Marcellini M, Devito R, et al. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes (Lond) 2008;32:381-387 (Pubitemid 351271778)
13. Sundaram SS, Zeitler P, Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr 2009;21:529-535.
14. Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology 2007;133:1814-1820.
15. Manco M, Bedogni G, Marcellini M, et al. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut 2008;57:1283-1287.
16. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:641-649 (Pubitemid 41233657)
17. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986-1998. JAMA 2001;286:2845-2848.
18. Potau N, Ibañez L, Riqué S, et al. Pubertal changes in insulin secretion and peripheral insulin sensitivity. Horm Res 1997;48:219-226 (Pubitemid 27462383)
19. Roberts EA. Pediatric nonalcoholic fatty liver disease (NAFLD): a 'growing' problem? J Hepatol 2007;46:1133-1142.
20. Moran A, Jacobs DR Jr, Steinberger J, et al. Changes in insulin resistance and cardiovascular risk during adolescence: establishment of differential risk in males and females. Circulation 2008;117:2361-2368 (Pubitemid 351653543)
21. Loomba R, Sirlin CB, Schwimmer JB, et al. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009;50:1282-1293.
22. Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
23. Carter-Kent C, Yerian LM, Brunt EM, et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009;50:1113-1120.
24. Nobili V, Marcellini M, Devito R, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006;44:458-465 (Pubitemid 44214885)
25. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of nonalcoholic fatty liver disease in children: a follow-up study for up to 20-years. Gut 2009;58:1538-1544.
26. Brunt EM, Kleiner DE, Wilson LA, et al. NASH Clinical Research Network. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD. Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009;49:809-820.
27. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009;9:299-314.
28. Malaguarnera M, Di Rosa M, Nicoletti Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med 2009;87:679-695.
29. Louthan MV, Barve S, McClain CJ, et al. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr 2005;147:835-838 (Pubitemid 41774843)
30. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007;27:44-54. (Pubitemid 46269804)
31. Tetri LH, Basaranoglu M, Brunt EM, et al. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008;295:G987-95.
32. Guo J, Friedman SL. Hepatic fibrogenesis. Semin Liver Dis 2007;27:413-426.
33. Balsano C, Alisi A, Nobili V. Liver fibrosis and therapeutic strategies: the goal for improving metabolism. Curr Drug Targets 2009;10:505-512.
34. Love-Osborne KA, Nadeau KJ, Sheeder J, et al. Presence of the metabolic syndrome in obese adolescents predicts impaired glucose tolerance and nonalcoholic fatty liver disease. J Adolesc Health 2008;42:543-548.
35. Ko JS, Yoon JM, Yang HR, et al. Clinical and histological features of nonalcoholic fatty liver disease in children. Dig Dis Sci 2009;54:2225-2230.
36. Nanda K. Non-alcoholic steatohepatitis in children. Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis. Pediatr Transplant 2004;8:613-618.
37. Sobhonslidsuk A, Jongjirasiri S, Thakkinstian A, et al. Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis. World J Gastroenterol 2007;13:3614-3618 (Pubitemid 47162270)
38. Jakobsen MU, Berentzen T, Sørensen TI, et al. Abdominal obesity and fatty liver. Epidemiol Rev 2007;29:77-87.
39. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33. (Pubitemid 44782752)
40. Chiloiro M, Riezzo G, Chiarappa S, et al. Relationship among fatty liver, adipose tissue distribution and metabolic profile in moderately obese children: an ultrasonographic study. Curr Pharm Des 2008;14:2693-2698.
41. Schwenzer NF, Springer F, Schraml C, et al. Noninvasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51:433-445.
42. Pinzani M, Vizzutti F, Arena U, et al. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008;5:95-106. (Pubitemid 351234279)
43. Nobili V, Vizzutti F, Arena U, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008;48:442-448.
44. Nobili V, Parkes J, Bottazzo G, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009;136:160-167.
45. Nobili V, Alisi A, Vania A, et al. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med 2009;7:21.
46. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008;48:119-128 (Pubitemid 351975537)
47. Nobili V, Manco M, Devito R, et al. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006;24:1553-1561 (Pubitemid 44915203)
48. Nobili V, Manco M, Ciampalini P, et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008;30:1168-1176 (Pubitemid 351978124)
49. Mathurin P, Deltenre P. Effect of binge drinking on the liver: an alarming public health issue? Gut 2009;58:613-667.